Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation
- 3 July 2025
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (10) , 3251-3262
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo Company
- Horizon 2020 Framework Programme
- H2020 Marie Skłodowska-Curie Actions (956146)
This publication has 45 references indexed in Scilit:
- Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial FibrillationJAMA Cardiology, 2024
- Difficult Intravenous Access in Older Adults with Cancer: Can Vein-Locating Technology Be Key for Vessel Health?2023
- The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasmaResearch and Practice in Thrombosis and Haemostasis, 2022
- Risk Factors Associated With Mortality and Neurologic Disability After Intracerebral Hemorrhage in a Racially and Ethnically Diverse CohortJAMA Network Open, 2022
- Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resamplingJournal of Pharmacokinetics and Pharmacodynamics, 2016
- Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolismJournal of Thrombosis and Thrombolysis, 2016
- Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment studyThe Journal of Clinical Pharmacology, 2015
- Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillationEuropean Journal of Clinical Pharmacology, 2014
- Population pharmacokinetic‐pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatmentThe Journal of Clinical Pharmacology, 2014
- Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic modelsJournal of Pharmacokinetics and Pharmacodynamics, 2011